Nephrology

Back to articles

Differing patterns of ESA, I.V. iron use influence mortality risks

KEY POINT

In a study recently published in JAMA, researchers discovered an elevated risk of mortality at U.S. dialysis centers that use larger doses of erythropoietin stimulating agent (ESAs) in patients with hematocrit levels of 33% or greater and those that use more I.V. iron in patients with hematocrit levels of 36% or greater.